Complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, and use thereof

Patent metadata

Field	Value
Publication number	US-9718860-B2
Application number	US-201013505705-A
Country	US
Kind code	B2
Filing date	Nov 3, 2010
Priority date	Nov 3, 2009
Publication date	Aug 1, 2017
Grant date	Aug 1, 2017

Abstract

The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.

First claim

What is claimed is:

1. A vaccine composition comprising a complex of a zinc oxide nanoparticle and a recombinant protein, wherein the recombinant protein comprises a zinc oxide-binding peptide and an antigen, and an immunocyte, wherein the complex is introduced into the immunocyte.

2. The vaccine composition of claim 1 , wherein the specific zinc oxide-binding peptide has the structure of the following Formula I or Formula II:
[(Arg-X 1 -X 2 -Arg) m -linker] n   [Formula 1]

[(Arg-X 1 -X 2 -Arg-Lys) m -linker] n   [Formula 2]

wherein,
X i is Pro, Ala, Thr, Gln, or Be;
X 2 is His, Be, Asn, or Arg;
m is an integer of 1 to 5; and
n is an integer of 1 to 100.

3. The vaccine composition of claim 1 , wherein the antigen is a tumor antigen.

4. The vaccine composition of claim 3 , wherein the tumor antigen is selected from the group consisting of a carcinoma embryonic antigen, survivin, MAGE-1, MAGE-2, MAGE-3, MAGE-12, BAGE, GAGE, NY-ESO-1, tyrosinase, TRP-1, TRP-2, gp100, MART-1, MC1R, Ig idiotype, CDK4, caspase-9, beta-catenin, CIA, BCR/ABL, mutated p21/ras, mutated p53, proteinase 3, WT1, MUC-1, normal p53, Her2/neu, PAP, PSA, PSMA, G250, HPV E6/E7, EBV LMP2a, HCV, HHV-8, alpha-fetoprotein, 5T4, onco-trophoblast, and glycoprotein.

5. The vaccine composition of claim 1 , wherein the immunocyte is a dendritic cell, T cell, or NK cell.

6. The vaccine composition of claim 1 , wherein the zinc oxide nanoparticle has a core-shell structure, and wherein the core is composed of a T1 or T2 contrast medium and the shell is composed of zinc oxide.

Assignees

• Cho Nam-Hyuk
• Cheong Taek-Chin
• Seong Seung-Yong
• Min Ji Hyun
• Wu Jun Hua
• Kim Young-Keun
• Univ Korea Res & Bus Found
• Snu R&Db Foundation

Inventors

• Cho Nam-Hyuk
• Cheong Taek-Chin
• Seong Seung-Yong
• Min Ji Hyun
• Wu Jun Hua
• Kim Young-Keun

Classifications

• A61K47/50

  the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• C07K17/14

  Peptides being immobilised on, or in, an inorganic carrier · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title